|
 Ohr's drug, Squalamine, was being tested in a mid-stage trial in
patients with age-related macular degeneration, the leading cause of
blindness among the elderly.
An interim analysis of trial data showed patients getting Squalamine
needed an average of 6.2 eye injections, while those on placebo
needed 6.4.
The main goal of the trial was to reduce the number of required
injections.
(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb
Chakrabarty)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
